NCT00686517View on ClinicalTrials.gov

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Hepatitis C
Interventions
BIOLOGICAL

Pegylated interferon alfa-2b

1.5 ug/kg/week SC for 12 or 24 weeks

DRUG

Ribavirin

Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks

All Listed Sponsors
collaborator

Bioikos Ambiente Srl

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00686517 - Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137) | Biotech Hunter | Biotech Hunter